Comparison

BPC-157 vs TB-500

Medically reviewed by Marko Maal · May 7, 2026

Reviewed by Marko Maal, MSc Pharmacy · University of Tartu · Pharmaceutical sciences — drug sourcing, formulation, regulatory review · Reviewed May 7, 2026

Reviewed for clinical and pharmacological accuracy by Marko Maal, MSc Pharmacy.

Dimension	BPC-157	TB-500
Mechanism	Body-protective compound — pentadecapeptide derived from gastric protein BPC	Synthetic 17-aa fragment of thymosin β-4 — actin-sequestering, cell migration
Best evidence for	Tendon, ligament, gut barrier, ulcer healing	Connective tissue migration, generalized soft-tissue recovery
Evidence tier	Tier 3 — animal RCTs + small human pilots	Tier 4 — animal data + clinical case reports
Half-life (sc)	~4 hours	~2–3 hours
Routes	SC, IM, oral (arginate salt)	SC, IM
Typical protocol	250–500 mcg twice daily, 4–6 weeks	2.0–2.5 mg twice weekly, 4–6 weeks loading then 1× weekly
FDA category	Interim Category 2 (under PCAC review July 2026)	Interim Category 2 (under PCAC review July 2026)
WADA status	Prohibited (S0) since Jan 2022	Prohibited (S2) since 2011
Cost / month	$80–$160 compounded	$200–$340 compounded

How do they actually differ?

Evidence tier: 3 — mechanism established by multiple animal RCTs (Sikiric 2010 for BPC-157; Goldstein 2005 and Malinda 1999 for TB-4/TB-500); human data limited to small pilots and case series.

BPC-157 and TB-500 share a marketing category — "recovery peptides" — but operate on different limbs of the tissue-repair cascade. BPC-157 is a 15-amino-acid pentadecapeptide derived from a fragment of human gastric juice protein (Body Protective Compound). Its dominant repair mechanism is VEGF-driven angiogenesis paired with fibroblast migration: it lays down vasculature and signaling for new tissue. The animal evidence is strongest in tendon-to-bone healing, ligament repair, and gut barrier reconstitution, with effective subcutaneous half-life around four hours. TB-500 is a synthetic 17-amino-acid fragment of thymosin beta-4, the body's main actin-sequestering protein. Its dominant mechanism is cytoskeletal reorganization: it lets cells migrate into a damaged site and remodel the actin scaffold. The half-life is shorter (~2-3 hours subcutaneously), and the strongest preclinical evidence is in cardiac, corneal, and broader connective-tissue migration models. The two peptides are mechanistically complementary rather than redundant — BPC builds the highway, TB-500 moves the trucks. The dosing column in the comparisonMatrix shows the practical consequence: BPC is dosed twice daily at microgram amounts; TB-500 is dosed twice weekly at milligram amounts.

Who should choose BPC-157?

Evidence tier: 3 — animal RCTs in tendon and gut models (Sikiric 2010); small human pilots in Achilles tendinopathy and inflammatory bowel disease.

BPC-157 is the better fit for users whose primary problem is tendon, ligament, or gut tissue. The peptide's preclinical evidence base maps tightly onto orthopedic soft-tissue injuries — Achilles tendinopathy, rotator cuff tears, medial collateral ligament strains, and labral repairs are where animal RCT data is most directly translatable. A second high-fit population is patients with chronic gut barrier disruption: leaky gut, NSAID-induced gastric injury, and inflammatory bowel disease pilots have shown the most consistent symptomatic response in human case series. The oral arginate salt formulation matters here — BPC-157 is the only peptide in the recovery class with credible oral bioavailability data, making it the only one practical for gut-targeted dosing. Cost is a third factor: at $80-$160/month compounded, BPC-157 runs roughly half what TB-500 costs. Patients with isolated, mechanistically-targeted injuries who want the most-evidenced single peptide should start here. Athletes subject to WADA testing should not use BPC-157 — it has been on the prohibited list (Section S0) since January 2022. Discuss any post-surgical recovery protocol with your sports-medicine physician.

Who should choose TB-500?

Evidence tier: 4 — animal data including Malinda 1999 dermal wound model and Goldstein 2005 actin-binding mechanism; human evidence limited to case reports.

TB-500 is the better fit for users with diffuse, multi-tissue, or systemic recovery demands rather than a single-injury target. The actin-dynamics mechanism is upstream of more tissue types than BPC-157 hits — cardiac muscle (post-MI repair models), corneal epithelium (RGN-259 ophthalmic data uses the parent thymosin beta-4), and dermal wound healing all show response in animal work. Patients recovering from polytrauma, multi-area orthopedic surgery, or autoimmune-driven connective tissue inflammation are reasonable candidates. The dosing schedule is more practical for users who dislike daily injections — two-times-weekly dosing during a loading phase, then once weekly maintenance, is a substantially lower compliance burden than BPC's twice-daily schedule. Stacking with BPC-157 is the most common clinical pattern for serious orthopedic recovery; the mechanisms layer rather than overlap. Cost is higher ($200-$340/month compounded) reflecting the larger dose-per-injection. As with BPC-157, athletes subject to WADA testing should not use TB-500 — it has been on the prohibited list (Section S2) since 2011. Discuss any extended TB-500 protocol with your physician.

What does the evidence base actually say?

Evidence tier: 3 — Sikiric 2010 review compiles 100+ BPC-157 animal studies; Goldstein 2005 and Malinda 1999 anchor TB-4/TB-500 mechanism; no head-to-head RCT exists.

The BPC-157 preclinical evidence is unusually deep for a peptide of its regulatory tier. The Sikiric group at the University of Zagreb has published over a hundred animal-model studies across rat, mouse, and rabbit, covering tendon, ligament, gut, vascular, and central-nervous-system endpoints. The 2010 review is the canonical mechanism summary — VEGF, NO, and growth-factor receptor pathways. Human data is limited to small Croatian pilots in inflammatory bowel disease and uncontrolled case series in tendinopathy. The TB-500 evidence base is narrower but anchored on parent-molecule (thymosin beta-4) data: Goldstein 2005 established the actin-sequestering mechanism, Malinda 1999 demonstrated dermal wound acceleration, and the RGN-259 ophthalmic Phase 2 data (2015) showed a 26-day improvement window in severe dry eye disease. There is no head-to-head RCT comparing BPC-157 and TB-500 in any indication, and there is no FDA-quality Phase 2 or Phase 3 trial in either peptide. The comparison rests on mechanism inference and parallel animal-model evidence, not on directly comparable clinical endpoints. Anyone framing either peptide as "clinically proven" is overstating the evidence base.

Cost, access, and regulatory comparison

Evidence tier: 2 — pricing reflects compounded retail in April 2026; FDA category status from PCAC interim list.

Both BPC-157 and TB-500 are FDA Interim Category 2 — meaning they may be compounded by 503A pharmacies pending the next Pharmacy Compounding Advisory Committee (PCAC) review, scheduled for July 2026. Neither has an approved drug application; both are off-label, compounded-only products in the United States. Compounded retail runs $80-$160/month for BPC-157 and $200-$340/month for TB-500, reflecting the much larger absolute dose required for TB-500. Telehealth access has expanded since 2024 but remains state-dependent; some states require an in-person evaluation before compounded peptide prescribing. Both peptides remain on the WADA prohibited list — BPC-157 as S0 (non-approved substances) since January 2022, TB-500 as S2 (peptide hormones) since 2011. The PCAC July 2026 review is the next regulatory inflection point; if either peptide is moved off Interim Category 2, access could change materially. See the FDA 503A bulks list for current category status.

References

Sikiric P, Seiwerth S, Rucman R, et al. 2010. Stable gastric pentadecapeptide BPC 157-NEW therapy of inflammatory bowel diseases, ulcers, and inflammatory and other organ lesions. Curr Pharm Des. PMID 20388964
Goldstein AL, Hannappel E, Kleinman HK. 2005. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. PMID 16099219
Malinda KM, Sidhu GS, Mani H, et al. 1999. Thymosin beta4 accelerates wound healing. J Invest Dermatol. PMID 10469335
Sosne G, Dunn SP, Kim C. 2015. Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. PMID 25826322

TB-500 — community signal

Recent posts and videos mentioning TB-500 from the cron-ingested Reddit + X pipelines and the curated /experts directory. Not endorsement — directional context only.

BPC-157 — community signal

Recent posts and videos mentioning BPC-157 from the cron-ingested Reddit + X pipelines and the curated /experts directory. Not endorsement — directional context only.

Community Notes

0 approved · moderated

Structured notes from readers — context, citations, corrections, and first-hand experience. Every note is moderated before it appears. Notes do not replace medical review; they supplement it.

No approved notes yet.

Know something that should be on this page? A citation, clarification, or dispute? Sign in and submit the first note.

Submission interface coming in Phase 2. For now, notes are authored in Studio. See the Community Guidelines for moderation criteria.